Clinical Trials Logo

Filter by:
NCT ID: NCT00247299 Active, not recruiting - Port Wine Stain Clinical Trials

Evaluation and Optimization of the Technical and Clinical Performance of the Lumenis ONE Platform

Start date: May 2005
Phase: N/A
Study type: Interventional

The Intense Pulsed Light (IPL) technology, by selective phototermolysis, is used for eliminating, among other application, benign vascular lesions and unwanted leg veins. Light energy heats the deeper structures of the skin. IPL devices provide a broad wavelength spectrum of 515 to 1200 nm and fluence from 10 to 40 J/cm at o.5-1 Hz.The light is focused by a reflector and then transmitted through various filters that cut off the lower wavelength range of the emitted light; therefore, only those wavelengths longer than these of the filters are transmitted. objectives: 1. evaluate and optimize the clinical performance of the Luminis ONE platform for each of the aforementioned clinical applications. 2. Reconfirm the parameter settings for each of the aforementioned clinical applications. 3. Confirm the user friendly design of the device, in aspects of software (user interface) and various technical operational features.

NCT ID: NCT00247117 Recruiting - Liver Diseases Clinical Trials

Metformin in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)

Start date: January 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effect of metformin on biochemical and histological findings in NAFLD patients with insulin resistance syndrome.

NCT ID: NCT00247104 Not yet recruiting - Premature Birth Clinical Trials

The Use of Cranberries in Women With Preterm Premature Rupture of Membranes

Start date: May 2007
Phase: N/A
Study type: Interventional

Cranberries have been proved to reduce the rate of urinary tract infections in a population of women with recurrent urinary tract infections in previous studies. The purpose of the study is to examine the efficacy of cranberries in pregnant women with preterm premature rupture of membranes in a)prolonging the latent period (=the time period between the time the water broke and delivery of the fetus) and b)reduction of infectious morbidity of both the mother and infant.

NCT ID: NCT00247039 Recruiting - Neutropenia Clinical Trials

Garlic in Patients With Febrile Neutropenia

Start date: June 2006
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the clinical effects of garlic in preventing and treatment of patients with chemotherapy related febrile neutropenia.These patients have a very high incidence of infections which are not routinely covered by the standard empiric therapy. Adding a non- toxic and possibly effective therapy may reduce the risk for infections, synergize the empiric antibiotic treatment and may lessen the need for broader spectrum and more severe side effects.

NCT ID: NCT00247026 Withdrawn - Clinical trials for Myelodysplastic Syndrome

The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic Syndromes

Start date: April 2007
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the clinical effects of coenzyme Q10 and Curcumin in improving the cytopenias of patients with myelodysplastic syndromes. we propose to explore the efficacy of the natural compounds curcumin and CoQ10 in MDS because these two agents possess many of the effects that are desirable in MDS.

NCT ID: NCT00244764 Completed - Clinical trials for Carcinoma, Renal Cell

GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma

Start date: October 2005
Phase: Phase 2
Study type: Interventional

Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell Carcinoma (RCC). After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.

NCT ID: NCT00244751 Completed - Cirrhosis, Liver Clinical Trials

Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects

Start date: November 2, 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine the safety and effectiveness of GI262570 compared to placebo (a pill that looks exactly like GI262570 but contains no active medicine) in improving specific tests that indicate the degree of liver fibrosis (scarring). Subjects who are enrolled in the study must have had prior treatment with interferon (either pegylated or standard interferon) plus ribavirin for at least 12 weeks to treat their hepatitis C, but either failed to clear the virus or didn't tolerate the treatment.

NCT ID: NCT00244738 Completed - Prolonged Pregnancy Clinical Trials

The Use of Castor Oil as a Labor Initiator in Post-date Pregnancies

Start date: February 2006
Phase: N/A
Study type: Interventional

The purpose of the study is to determine whether castor oil is effective in inducing labor.

NCT ID: NCT00244725 Completed - Pulmonary Embolism Clinical Trials

Odiparcil For The Prevention Of Venous Thromboembolism

Start date: September 2005
Phase: Phase 2
Study type: Interventional

Odiparcil is being studied to determine if it can prevent blood clots from forming after a total knee replacement and also to prove that odiparcil is safe.

NCT ID: NCT00243789 Completed - Clinical trials for Muscular Dystrophy, Duchenne

Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy

Start date: September 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to see if male children with Duchenne muscular dystrophy (DMD) have changes in strength when given the drug Pentoxifylline as a rescue treatment. A total of 64 subjects are expected to participate through all other centers of the Cooperative International Neuromuscular Research Group (CINRG) worldwide. The primary purpose of this study is to see whether the addition of pentoxifylline to a steroid regimen is effective in treating deteriorating muscle strength by comparing the muscle strength of PTX treated subjects and placebo treated subjects.